Acquired thrombotic thrombocytopenic purpura development of an autoimmune response

Hamostaseologie

Volumn 33, Issue 2, 2013, Pages 121-130

  Schaller, M ^a   Studt, J D ^b   Voorberg, J ^c   Kremer Hovinga, J A ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

ADAMTS13; Autoantibodies; Autoimmunity; Thromobotic thrombocytopenic purpura; TTP

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; POLYMER; RITUXIMAB; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CLEARANCE; CLONAL ANERGY; ENZYME DEFICIENCY; ENZYME REGULATION; HUMAN; IMMUNE DYSREGULATION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INCIDENCE; ISCHEMIA; MORTALITY; PATHOGENESIS; PLASMAPHERESIS; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; RELAPSE; THERAPY; THROMBOCYTE AGGREGATION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; AUTOIMMUNITY; B-LYMPHOCYTES; HUMANS; MODELS, IMMUNOLOGICAL; PURPURA, THROMBOTIC THROMBOCYTOPENIC; T-LYMPHOCYTES; VON WILLEBRAND FACTOR;

EID: 84881520803     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/HAMO-12-12-0023     Document Type: Article

References (99)

1. Abbas AK, Lichtman AH. Introduction to the immune system. In: Schmitt W (ed). Basic Immunology: Saunders Elsevier 2011, p. 1-22.
2. Diamant E, Melamed D. Class switch recombination in B lymphopoiesis: a potential pathway for B cell autoimmunity. Autoimmun Rev 2004; 3: 464-469.
3. Burnet FM. Immunological recognition of self. Science 1961; 133: 307-311.
4. Pike BL, Boyd AW, Nossal GJ. Clonal anergy: the universally anergic B lymphocyte. Proc Natl Acad Sci USA 1982; 79: 2013-2017.
5. Jerne NK. Towards a network theory of the immune system. Annales d' Immunologie 1974; 125: 373-389.
6. Curotto de Lafaille MA, Lafaille JJ. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 2009; 30: 626-635.
7. Edwards JC, Cambridge G, Abrahams VM. Do selfperpetuating B lymphocytes drive human autoimmune disease? Immunology 1999; 97: 188-196.
8. Tisch R, Wang B. Dysrulation of T cell peripheral tolerance in type 1 diabetes. Adv Immunol 2008; 100: 125-149.
9. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006; 6: 394-403.
10. Foreman AL, Van de Water J, Gougeon ML, Gershwin ME. B cells in autoimmune diseases: insights from analyses of immunoglobulin variable (Ig V) gene usage. Autoimmun Rev 2007; 6: 387-401.
11. Moake JL, Rudy CK, Troll JH et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307: 1432-1435.
12. Ferrari S, Mudde GC, Rieger M et al. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2009; 7: 1703-1710.
13. Pos W, Sorvillo N, Fijnheer R et al. Residues Arg568 and Phe592 contribute to an antigenic surface for anti-ADAMTS13 antibodies in the spacer domain. Haematologica 2011; 96: 1670-1677.
14. Bettoni G, Palla R, Valsecchi C et al. ADAMTS- 13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2012; 10: 1556-1565.
15. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med 2012; 366: 539-551.
16. Ferrari S, Scheiflinger F, Rieger M et al. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 2007; 109: 2815-2822.
17. Rieger M, Mannucci PM, Kremer Hovinga JA et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 2005; 106: 1262-1267.
18. Knöbl P. Unraveling the immunologic response in thrombotic thrombocytopenic purpura. J Thromb Haemost 2006; 4: 2352-2354.
19. Froehlich-Zahnd R, George JN, Vesely SK et al. Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica 2012; 97: 297-303.
20. Levy GG, Nichols WC, Lian EC et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-494.
21. Luken BM, Turenhout EA, Hulstein JJ et al. The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 2005; 93: 267-274.
22. Zheng XL, Wu H, Shang D et al. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica 2010; 95: 1555-1562.
23. Klaus C, Plaimauer B, Studt JD et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood 2004; 103: 4514-4519.
24. Yamaguchi Y, Moriki T, Igari A et al. Epitope analysis of autoantibodies to ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Thromb Res 2011; 128: 169-173.
25. Schaller M, Bigler C, Danner D et al. Autoantibodies against C1q in systemic lupus erythematosus are antigen-driven. J Immunol 2009; 183: 8225-8231.
26. Schaller M, Burton DR, Ditzel HJ. Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease. Nat Immunol 2001; 2: 746-753.
27. Luken BM, Turenhout EA, Kaijen PH et al. Amino acid regions 572-579 and 657-666 of the spacer domain of ADAMTS13 provide a common antigenic core required for binding of antibodies in patients with acquired TTP. Thromb Haemost 2006; 96: 295-301.
28. Pos W, Luken BM, Kremer Hovinga JA et al. VH1-69 germline encoded antibodies directed towards ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2009; 7: 421-428.
29. Siegel DL. Translational applications of antibody phage display. Immunol Res 2008; 42: 118-131.
30. Pos W, Crawley JT, Fijnheer R et al. An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF. Blood 2010; 115: 1640-1649.
31. Jin SY, Skipwith CG, Zheng XL. Amino acid residues Arg(659), Arg(660), and Tyr(661) in the spacer domain of ADAMTS13 are critical for cleavage of von Willebrand factor. Blood 2010; 115: 2300-2310.
32. Akiyama M, Takeda S, Kokame K et al. Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor. Proc Natl Acad Sci USA 2009; 106 : 19274-19279.
33. Tao Z, Peng Y, Nolasco L et al. Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions. Blood 2005; 106: 4139-4145.
34. Tao Z, Wang Y, Choi H et al. Cleavage of ultralarge multimers of von Willebrand factor by C-terminaltruncated mutants of ADAMTS-13 under flow. Blood 2005; 106: 141-143.
35. Zhang P, Pan W, Rux AH et al. The cooperative activity between the carboxyl-terminal TSP1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow. Blood 2007; 110: 1887-1894.
36. Banno F, Chauhan AK, Kokame K et al. The distal carboxyl-terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formation. Blood 2009; 113: 5323-5329.
37. Vomund AN, Majerus EM. ADAMTS13 bound to endothelial cells exhibits enhanced cleavage of von Willebrand factor. J Biol Chem 2009; 284: 30925-30932.
38. Luken BM, Kaijen PH, Turenhout EA et al. Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2006; 4: 2355-2364.
39. Ferrari S, Knöbl P, Kolovratova V et al. Inverse correlation of free and immune complex-sequestered anti-ADAMTS13 antibodies in a patient with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2012; 10: 156-158.
40. Scully M, McDonald V, Cavenagh J et al. A phase II study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011; 118: 1746-1753.
41. Iioka F, Shimomura D, Ishii T et al. Short- and long-term effects of rituximab for the treatment of thrombotic thrombocytopenic purpura: four case reports. Int J Hematol 2012; 96: 506-512.
42. George JN. Corticosteroids and rituximab as adjunctive treatments for thrombotic thrombocytopenic purpura. Am J of Hematol 2012; 87 (Suppl 1): S88-S91.
43. Tun NM, Villani GM. Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis. J Thromb Thrombolysis 2012; 34: 347-359.
44. Yassa SK, Blessios G, Marinides G, Venuto RC. Anti-CD20 monoclonal antibody (rituximab) for life-threatening hemolytic-uremic syndrome. Clin Transplant 2005; 19: 423-426.
45. Yomtovian R, Niklinski W, Silver B et al. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol 2004; 124: 787-795.
46. Zheng X, Pallera AM, Goodnough LT et al. Remission of chronic thrombotic thrombo - cytopenic purpura after treatment with cyclo - phosphamide and rituximab. Ann Intern Med 2003; 138: 105-108.
47. Ahmad A, Aggarwal A, Sharma D et al. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP). Am J Hematol 2004; 77: 171-176.
48. Uchida J, Hamaguchi Y, Oliver JA et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004; 199: 1659-1669.
49. Di Gaetano N, Cittera E, Nota R et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003; 171: 1581-1587.
50. Teeling JL, French RR, Cragg MS et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas Blood 2004; 104: 1793-1800.
51. Gong Q, Ou Q, Ye S et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005; 174: 817-826.
52. Caramazza D, Quintini G, Abbene I et al. Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura- haemolytic uraemic syndrome. Blood Transfusion 2010; 8: 203-210.
53. Froissart A, Buffet M, Veyradier A et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med 2012; 40: 104-111.
54. Rehnberg M, Amu S, Tarkowski A et al. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther 2009; 11: R123.
55. Yoshida T, Mei H, Dorner T et al. Memory B and memory plasma cells. Immunol Rev 2010; 237: 117-139.
56. Popa C, Leandro MJ, Cambridge G, Edwards JC. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) 2007; 46: 626-630.
57. Vallerskog T, Gunnarsson I, Widhe M et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2007; 122: 62-74.
58. Mamani-Matsuda M, Cosma A, Weller S et al. The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. Blood 2008; 111: 4653-4659.
59. Dunn-Walters DK, Isaacson PG, Spencer J. Analysis of mutations in immunoglobulin heavy chain variable region genes of microdissected marginal zone (MGZ) B cells suggests that the MGZ of human spleen is a reservoir of memory B cells. J Exp Med 1995; 182: 559-566.
60. Aqui NA, Stein SH, Konkle BA et al. Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpura. J Clin Apher 2003; 18: 51-54.
61. Kappers-Klunne MC, Wijermans P, Fijnheer R et al. Splenectomy for the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 2005; 130: 768-776.
62. Kremer Hovinga JA, Vesely SK, Terrell DR et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115: 1500-1511.
63. Dorner T, Kaufmann J, Wegener WA et al. Initial clinical trial of epratuzumab (humanized anti- CD22 antibody) for immunotherapy of s ystemic lupus erythematosus. Arthritis Res Ther 2006; 8: R74.
64. Dorner T, Shock A, Smith KG. CD22 and auto - immune disease. Int Rev Immunol 2012; 31: 363-738.
65. Vallera DA, Todhunter DA, Kuroki DW et al. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia / lymphoma. Clin Cancer Res 2005; 11: 3879-3888.
66. Mackay F, Sierro F, Grey ST, Gordon TP. The BAFF/ APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun 2005; 8: 243-265.
67. Thompson JS, Bixler SA, Qian F et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001; 293: 2108-2111.
68. Mackay F, Woodcock SA, Lawton P et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999; 190: 1697-1710.
69. Gross JA, Dillon SR, Mudri S et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. Impaired B cell maturation in mice lacking BLyS. Immunity 2001; 15: 289-302.
70. Gross JA, Johnston J, Mudri S et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404: 995-999.
71. Lesley R, Xu Y, Kalled SL et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004; 20: 441-453.
72. Stohl W, Hiepe F, Latinis KM et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2328-2337.
73. Genovese MC, Becker JC, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005; 353: 1114-1123.
74. Lindvall JM, Blomberg KE, Valiaho J et al. Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol Rev 2005; 203: 200-215.
75. Wong BR, Grossbard EB, Payan DG, Masuda ES. Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opin Investig Drugs 2004; 13: 743-762.
76. Venanzi ES, Benoist C, Mathis D. Good riddance: Thymocyte clonal deletion prevents autoimmunity. Curr Opin Immunol 2004; 16: 197-202.
77. Starr R, Hilton DJ. Defining control: regulation of dendritic cell activation and immune homeostasis by SOCS1. Immunity 2003; 19: 308-309.
78. Sorvillo N, Pos W, van den Berg LM et al. The macrophage mannose receptor promotes uptake of ADAMTS13 by dendritic cells. Blood 2012; 119: 3828-3835.
79. Coppo P, Busson M, Veyradier A et al. HLADRB1, 11: a strong risk factor for acquired severe ADAMTS13 deficiency-related idiopathic thrombotic thrombocytopenic purpura in Caucasians. Thromb Heamost 2010; 8: 856-859.
80. Pos W, Luken BM, Sorvillo N et al. Humoral immune response to ADAMTS13 in acquired TTP. J Thromb Heamost 2011; 9: 1285-1291.
81. Mariani M, Cairo A, Palla R et al. B and T lymphocytes in acquired thrombotic thrombocytopenic purpura during disease remission. Thromb Res 2011; 128: 590-592.
82. Gambineri E, Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheumatol 2003; 15: 430-435.
83. Kim CH. Molecular targets of FoxP3+ regulatory T cells. Mini Rev Med Chem 2007; 7: 1136-1143.
84. Scully M, Brown J, Patel R et al. Human leukocyte antigen association in idiopathic thrombotic thrombocytopenic purpura: evidence for an immunogenetic link. J Thromb Haemost 2010; 8: 257-262.
85. John ML, Hitzler W, Scharrer I. The role of human leukocyte antigens as predisposing and/or protective factors in patients with idiopathic thrombotic thrombocytopenic purpura. Ann Hematol 2012; 91: 507-510.
86. Studt JD, Hovinga JA, Radonic R et al. Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins. Blood 2004; 103: 4195-4197.
87. Cataland SR, Wu HM. Targeting the inhibitor of ADAMTS13 in thrombotic thrombocytopenic purpura. Expert Opin Pharmacothe 2007; 8: 437-444.
88. Cataland SR, Jin M, Lin S et al. Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura. Am J Hematol 2008; 83: 911-915.
89. Cataland SR, Jin M, Ferketich AK et al. An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 2007; 136: 146-149.
90. Van der Plas RM, Schiphorst ME, Huizinga EG et al. Von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood 1999; 93: 3798-3802.
91. Peyvandi F, Siboni SM, Lambertenghi Deliliers D et al. Prospective study on the behaviour of the metalloprotease ADAMTS13 and of von Willebrand factor after bone marrow transplantation. Br J Haematol 2006; 134: 187-195.
92. Kentouche K, Zintl F, Angerhaus D et al. Von Willebrand factor-cleaving protease (ADAMTS13) in the course of stem cell transplantation. Semin Thromb Hemost 2006; 32: 98-104.
93. Hershko K, Simhadri V, Blaisdell A et al. Cyclosporin A impairs the secretion and activity of ADAMTS13. J Biol Chem 2012; 287: 44361-44371.
94. Mathis D, Benoist C. A decade of AIRE. Nat Rev Immunol 2007; 7: 645-650.
95. Fuchs TA, Kremer Hovinga JA, Schatzberg D et al. Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood 2012; 120: 1157-1164.
96. Plaimauer B, Kremer Hovinga JA, Juno C et al. Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost 2011 ;9: 936-944.
97. Jian C, Xiao J, Gong L et al. Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Blood 2012; 119: 3836-3843.
98. Coppo P, Veyradier A. Current management and therapeutical perspectives in thrombotic thrombo cytopenic purpura. Presse Med 2012; 41: 163-176.
99. Kremer Hovinga JA, Voorberg J. Improving on nature: redesigning ADAMTS13. Blood 2012; 119: 3654-3655.